This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.

COMPETE Phase III Clinical Trial 

will evaluate the efficacy and safety of Targeted Radionuclide Therapy with 177Lu-Edotreotide / Solucin® in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET).

Patient Information

Patients and interested parties will find further information on the COMPETE trial subjects’ inclusion criteria as well as our listed participating clinical centers.

View Details >>

Healthcare Professionals

The trial will be conducted worldwide in 11 countries at 33 sites and is now open for recruitment. Healthcare professionals who are interested in enrolling patients will find comprehensive background information on this site.